Company profile TGTX

TG Therapeutics Inc
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope ...on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx". Show More
Quarter analysis & expected interestLast update: February 09 2024 02:15:05.

After 39 days of this quarter the interest is at 98.0. Based on that we can calculate that during remaining 52 days it will total up to 229.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019150
 244
62.7% QoQ		 209
-14.3% QoQ		 171
-18.2% QoQ
2020 319
112.7% YoY 86.5% QoQ		 369
51.2% YoY 15.7% QoQ		 367
75.6% YoY -0.5% QoQ		 401
134.5% YoY 9.3% QoQ
2021 486
52.4% YoY 21.2% QoQ		 332
-10.0% YoY -31.7% QoQ		 307
-16.3% YoY -7.5% QoQ		 400
-0.2% YoY 30.3% QoQ
2022 431
-11.3% YoY 7.8% QoQ		 379
14.2% YoY -12.1% QoQ		 191
-37.8% YoY -49.6% QoQ		 331
-17.2% YoY 73.3% QoQ
2023 317
-26.5% YoY -4.2% QoQ		 306
-19.3% YoY -3.5% QoQ		 288
50.8% YoY -5.9% QoQ		 263
-20.5% YoY -8.7% QoQ
2024 98
-69.1% YoY -62.7% QoQ		 - - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and TG Therapeutics search interestLast update: February 09 2024 02:15:04.
Correlation coefficient between keyword and revenue is -0.07
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 02:15:09.

The average 5 years interest of TG Therapeutics was 24.36 per week.
The last year interest of TG Therapeutics compared to the last 5 years has changed by -11.04%.
The interest for TG Therapeutics is seasonal.
The last year interest is quite higher compared to 5 years ago. It has increased by 21.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics profile to provide analysis

Correlation between past revenue and TG Therapeutics profile search interest

There is not enough data for TG Therapeutics profile to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics profile to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics company to provide analysis

Correlation between past revenue and TG Therapeutics company search interest

There is not enough data for TG Therapeutics company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics healthcare to provide analysis

Correlation between past revenue and TG Therapeutics healthcare search interest

There is not enough data for TG Therapeutics healthcare to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics healthcare to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics biopharmaceutical to provide analysis

Correlation between past revenue and TG Therapeutics biopharmaceutical search interest

There is not enough data for TG Therapeutics biopharmaceutical to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics biopharmaceutical to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics B-cell diseases to provide analysis

Correlation between past revenue and TG Therapeutics B-cell diseases search interest

There is not enough data for TG Therapeutics B-cell diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics B-cell diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics treatments to provide analysis

Correlation between past revenue and TG Therapeutics treatments search interest

There is not enough data for TG Therapeutics treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics CD20 monoclonal antibody to provide analysis

Correlation between past revenue and TG Therapeutics CD20 monoclonal antibody search interest

There is not enough data for TG Therapeutics CD20 monoclonal antibody to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics CD20 monoclonal antibody to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics multiple sclerosis to provide analysis

Correlation between past revenue and TG Therapeutics multiple sclerosis search interest

There is not enough data for TG Therapeutics multiple sclerosis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics multiple sclerosis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics Umbralisib to provide analysis

Correlation between past revenue and TG Therapeutics Umbralisib search interest

There is not enough data for TG Therapeutics Umbralisib to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics Umbralisib to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics PI3K-delta inhibitor to provide analysis

Correlation between past revenue and TG Therapeutics PI3K-delta inhibitor search interest

There is not enough data for TG Therapeutics PI3K-delta inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics PI3K-delta inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics CLL to provide analysis

Correlation between past revenue and TG Therapeutics CLL search interest

There is not enough data for TG Therapeutics CLL to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics CLL to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics lymphoma to provide analysis

Correlation between past revenue and TG Therapeutics lymphoma search interest

There is not enough data for TG Therapeutics lymphoma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics lymphoma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TG Therapeutics CD19 antibody. to provide analysis

Correlation between past revenue and TG Therapeutics CD19 antibody. search interest

There is not enough data for TG Therapeutics CD19 antibody. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TG Therapeutics CD19 antibody. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TGTX
Earnings date: 2024-02-27 After close
Company name: TG Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-06T17:52:25Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $70

2026-05-06T11:00:00Z

GlobeNewswire
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

2026-05-05T11:01:00Z

BusinessWire
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

2026-04-30T11:30:00Z

GlobeNewswire
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

2026-04-22T11:30:00Z

GlobeNewswire
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

2026-04-15T11:30:00Z

GlobeNewswire
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

2026-03-12T11:00:00Z

BusinessWire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

2026-03-09T11:30:00Z

GlobeNewswire
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

2026-03-06T12:30:00Z

GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

2026-03-02T12:01:00Z

BusinessWire
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

2026-02-26T12:00:00Z

GlobeNewswire
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

2026-02-23T12:30:00Z

GlobeNewswire
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

2026-02-17T12:30:00Z

GlobeNewswire
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

2026-02-08T21:17:55Z

GlobeNewswire
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

2026-02-06T12:30:00Z

GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum